prostate cancer

[Ca-A Cancer Journal For Clinicians] Scientists highlight key aspects of genetic testing in prostate cancer (PC), the role of clinicians, with a focus on primary care, the importance of obtaining a comprehensive family history, current germline testing guidelines, and the impact on precision PC care.

[International Journal of Biological Macromolecules] The authors discuss the role of TGF-β signaling in proliferation, metastasis and therapy response of prostate cancer cells and in order to improve knowledge towards its regulation, upstream mediators of TGF-β such as non-coding RNAs are described.

[Myovant Sciences] Myovant Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of ORGOVYX® for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

[Journal of Experimental & Clinical Cancer Research] Researchers described that RelB participated in the immune evasion of prostate cancer via cis/trans transcriptional upregulation of programmed death receptor ligand (PD-L1).

[Journal of Pineal Research] The authors revealed that melatonin concentration-dependently decreased the migratory and invasive abilities of two osteoblastic prostate cancer cell lines by inhibiting FAK, c-Src and NF-κB transcriptional activity via the melatonin MT1 receptor, which effectively inhibited integrin α2β1 expression.

[Journal of Translational Medicine] The effects of UAP1-like-1 (UAP1L1) on prostate cancer were investigated by detecting the proliferation, migration, invasion and apoptosis of prostate cancer cells in vitro using MTT, wound healing, Transwell and flow cytometry assay, and the tumor growth in vivo.